Detalhe da pesquisa
1.
Bone marrow microenvironment- induced regulation of Bcl-2 family members in multiple myeloma (MM): Therapeutic implications.
Cytokine
; 161: 156062, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36332463
2.
Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine-A prospective cohort study by the AGMT.
Am J Hematol
; 98(11): 1685-1698, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37548390
3.
Effect of cachexia on bone turnover in cancer patients: a case-control study.
BMC Cancer
; 21(1): 744, 2021 Jun 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34182958
4.
Correction: Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications.
Breast Cancer Res
; 26(1): 58, 2024 Apr 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38566222
5.
Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer.
Breast Cancer Res Treat
; 173(3): 585-596, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30374681
6.
Emerging protein kinase inhibitors for the treatment of multiple myeloma.
Expert Opin Emerg Drugs
; 24(3): 133-152, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31327278
7.
Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications.
Breast Cancer Res
; 18(1): 26, 2016 Feb 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-26921175
8.
In vitro and in vivo toxicity of 5-FdU-alendronate, a novel cytotoxic bone-seeking duplex drug against bone metastasis.
Invest New Drugs
; 33(4): 816-26, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25986684
9.
Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort.
World J Urol
; 33(6): 833-9, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25113804
10.
Favorable impact of PD1/PD-L1 antagonists on bone remodeling: an exploratory prospective clinical study and ex vivo validation.
J Immunother Cancer
; 12(5)2024 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38702145
11.
Real-World Evidence of Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer: An Austrian Multicenter Study.
Clin Genitourin Cancer
; 22(2): 458-466.e1, 2024 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38267304
12.
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease.
Proc Natl Acad Sci U S A
; 107(11): 5124-9, 2010 Mar 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-20194748
13.
Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidine-A Prospective Cohort Study by the AGMT.
Cancers (Basel)
; 15(5)2023 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36900181
14.
PI3K/p110{delta} is a novel therapeutic target in multiple myeloma.
Blood
; 116(9): 1460-8, 2010 Sep 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-20505158
15.
On the continuous (R)evolution of antibody-based and CAR T cell therapies in multiple myeloma: an early 2022 glance into the future.
Expert Opin Pharmacother
; 23(12): 1425-1444, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35829636
16.
Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-Group.
Cancers (Basel)
; 14(10)2022 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35626063
17.
The Impact of Primary Versus Secondary Muscle-invasive Bladder Cancer at Diagnosis on the Response to Neoadjuvant Chemotherapy.
Eur Urol Open Sci
; 41: 74-80, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35813257
18.
Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study.
Ther Adv Med Oncol
; 14: 17588359221086813, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35386956
19.
Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice.
J Clin Invest
; 118(2): 491-504, 2008 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-18219387
20.
The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications.
Br J Haematol
; 155(4): 438-48, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21923653